Drug: |
CS-1008 and Imatinib or Sunitinib |
|||
---|---|---|---|---|
Trial: |
A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors |
|||
Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Withdrawn |
Fox Chase Cancer Center333 Cottman Ave |
Principal Investigator: |
Margeret von Mehren, M.D. |
---|---|
Contact: |
1-888-FOX-CHASE |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Fox Chase Cancer Center Website: |
https://www.protonet.fccc.edu/fccc/pims/ |
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.